Jaffe, Elaine S
Mayo Clinic
National Institutes of Health, National Cancer Institute, Bethesda, MD.
Citations 12
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Clot, Guillem , Jares, Pedro , Giné, Eva , Navarro, Alba , Pinyol, Magda, Martin‐García, David , Demajo, Santiago , Espinet, Blanca , Salar, Antonio , Ferrer, Ana , Muntañola, Ana , Aymerich, Marta , Rauert‐Wunderlich, Hilka , Gascoyne, Randy D. , Delabie, Jan , López‐Guillermo, Armando , Ott, German , Wright, George W. , Staudt, Louis M. , Rosenwald, Andreas , Beà, Sı́lvia , Martín-Garcia, David , Demajo, Santiago , Salar, Antonio , Ferrer, Ana , Jaffe, Elaine S , Connors, Joseph M , Delabie, Jan , López-Guillermo, Armando , Beà, Sílvia , Campo, Elías , Royo, Cristina , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Rimsza, Lisa M. , Campo, Elı́as , Espinet, Blanca , Wright, George
Blood | May 16, 2018 | Volume: 132 | Issue: 4 | Pages: 413-422
Key PointsA new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Castellar, Edgardo R. Parrilla , Jaffe, Elaine S. , Said, Jonathan , Ketterling, Rhett P. , Knudson, Ryan A., Sidhu, Jagmohan S. , Karikehalli, Shridevi, Jiang, Liuyan , Vasmatzis, George , Ondrejka, Sarah L. , Nicolae, Alina , Grogg, Karen L., Allmer, Cristine, Ristow, Kay M., Wilson, Wyndham H. , Macon, William R. , Cerhan, James R. , Ansell, Stephen M. , Maurer, Matthew J. , Feldman, Andrew L. , Parrilla Castellar, Edgardo R, Law, Mark E. , Doǧan, Ahmet , Feldman, Andrew L , Swerdlow, Steven H. , Hsi, Eric D. , Gibson, Sarah E. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Jaffe, Elaine S , Ketterling, Rhett P
Blood | June 3, 2014 | Volume: 124 | Issue: 9 | Pages: 1473-1480
Key Points ALK-negative ALCLs have chromosomal rearrangements of DUSP22 or TP63 in 30% and 8% of cases, respectively. DUSP22-rearranged cases have favorable outcomes similar to ALK-positive ALCLs, whereas other genetic subtypes have inferior outcomes.